Patients treated by the Trust

Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments: Revolade (eltrombopag), Nplate (romiplostim), Doptelet (avatrombopag), Tavlesse (fostamatinib)

From September 2021 to February 2022 – 32 patients

Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?
Please see table at question 3 below.

Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with: rituximab, mycophenolate mofetil, surgery (splenectomy)

Please see below data held within the pharmacy department for the reporting period 01/10/2021 to 31/03/2022. Pharmacy records do not show the indication the drug was prescribed for, therefore this data is for how many patients for any indication, not just ITP. Please note that if the drug is not listed, it is because it has not been issued during this time period.

AVATROMBOPAG (DOPTELET)
Number of patients: <5

ELTROMBOPAG
Number of patients: 10

ELTROMBOPAG (REVOLADE) – HOMECARE
Number of patients: 17

MYCOPHENOLATE
Number of patients: 33

RITUXIMAB (MABTHERA)
Number of patients: 17

RITUXIMAB (RIXATHON)
Number of patients: 7

RITUXIMAB (TRUXIMA)
Number of patients: 71

ROMIPLOSTIM
Number of patients: 6

Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

No trials currently for this condition